Hidradenitis Suppurativa Clinical Trial Landscape

The hidradenitis suppurativa trial landscape in 2026

Hidradenitis suppurativa has gone from a commercially overlooked dermatological condition to one of the most actively contested therapeutic areas in immunology. Adalimumab's (Humira) approval in 2015 validated the commercial case. Secukinumab's (Cosentyx) approval confirmed the market. Now 12 Phase 3 programs are active simultaneously — testing JAK inhibitors, BTK inhibitors, dual IL-1 blockade, IL-17A/F biologics, and oral small molecules across five major sponsors.

The field expanded materially in late 2024 when Novartis opened two Phase 3 trials of remibrutinib, a BTK inhibitor, in HS. This is the same mechanism gaining ground in autoimmune indications (CLL, lupus, Sjögren's). Its entry into Phase 3 in HS brings the total competing mechanisms to five — and raises the stakes for every existing Phase 3 asset.

Current HS trial activity (as of early 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

Phase 3 HS trials — detailed view

All 12 active Phase 3 hidradenitis suppurativa trials as of early 2026:

The HS competitive landscape in 2026

Why HS is commercially important

Hidradenitis suppurativa affects approximately 1% of the global population and is significantly underdiagnosed. The disease burden is high — chronic pain, recurrent abscesses, and significant quality-of-life impact — but effective treatments remain limited. Adalimumab (Humira) was the first approved biologic, and secukinumab (Cosentyx) followed. Both set commercial precedent: the HS market accepts biologics at full specialty pricing ($25,000–$50,000+ annually), and the unmet need remains substantial.

Remibrutinib: BTK inhibition enters Phase 3 in HS

The most significant recent development in the HS pipeline is Novartis's decision to open two Phase 3 trials of remibrutinib — a covalent BTK inhibitor — in HS (RECHARGE 1, NCT06799000; RECHARGE 2, NCT06840392). BTK is expressed on B cells, mast cells, and macrophages and has been validated in oncology (ibrutinib, zanubrutinib). Its entry into HS Phase 3 represents a new mechanistic hypothesis: that B cell and mast cell signaling plays a meaningful role in HS pathogenesis, distinct from the TNF/IL-17/IL-1 pathways targeted by existing agents. If remibrutinib succeeds, it would be the first BTK inhibitor approved in dermatology.

Incyte's four-program strategy

Incyte is the most prolific HS sponsor by program count. Povorcitinib (selective JAK1) completed pivotal Phase 3 trials and is now in long-term safety and rollover studies. The ruxolitinib cream program (TRuE-HS1, TRuE-HS2) tests a topical JAK1/2 inhibitor — a route that avoids systemic JAK inhibition and its associated safety concerns. Four active Phase 3 programs from a single company in one indication reflects exceptional commercial conviction. Incyte is positioning itself as the HS category leader across both oral and topical mechanisms.

AbbVie's dual mechanism play

AbbVie has two Phase 3 assets in HS. Upadacitinib (Rinvoq) is a JAK1 inhibitor already approved in several inflammatory diseases — the HS Phase 3 is an indication expansion for an established compound with known safety profile. Lutikizumab targets both IL-1α and IL-1β simultaneously — a differentiated hypothesis versus TNF/IL-17 agents that have set the current standard. The dual IL-1 blockade theory is that HS is driven by upstream IL-1 signaling, and that blocking only one isoform leaves the other active.

Phase 2 pipeline: the next wave

Thirteen Phase 2 trials signal continued investment from sponsors not yet in Phase 3:

• Sanofi: Two Phase 2 assets — SAR445399 (NCT07225569) and brivekimig (NCT07170917). Two assets in Phase 2 simultaneously signals active HS indication investment.
• Takeda: Zasocitinib (JAK1/TYK2 inhibitor, NCT07244263) — the TYK2 component is mechanistically distinct from pure JAK1 inhibitors, targeting IL-23/IL-12 signaling.
• Merck: Tulisokibart (NCT06956235) — anti-TL1A antibody previously studied in IBD, now testing the TL1A hypothesis in HS.
• Insmed: Brensocatib (NCT06685835) — a DPP1 inhibitor that reduces neutrophil serine protease activity. Completely novel mechanism in HS.
• Sonoma Bio: SBT777101 (NCT06361836) — a Treg cell therapy. First cellular therapy to enter Phase 1 in HS.

What DataLookout monitors for hidradenitis suppurativa

Configure your profile with condition and mechanism keywords for targeted HS monitoring:

• Condition terms: "hidradenitis suppurativa", "HS", "acne inversa", "Hurley stage"
• By mechanism: "JAK inhibitor", "JAK1", "IL-1", "IL-17", "biologic", "bimekizumab", "lutikizumab", "povorcitinib"
• By population: "pediatric hidradenitis", "adolescent HS", "severe HS", "moderate-to-severe"
• By sponsor: Monitor specific company programs — enter "AbbVie" or "UCB" combined with "hidradenitis" for sponsor-specific intelligence

Who uses HS trial monitoring

Dermatology business development teams

BD professionals at dermatology-focused pharma and biotech track competitor HS trial activity daily. A new Phase 2 registration from an emerging biotech signals a potential licensing opportunity or competitive threat years before readout. In a field where three Phase 3 programs are running simultaneously, knowing when a fourth enters Phase 2 shapes portfolio decisions early.

Immunology analysts and healthcare investors

HS is a commercially validated indication with well-established pricing. Investors tracking AbbVie, UCB, Incyte, and Sanofi use Phase 2/3 trial registrations as leading indicators of pipeline value. Status changes — particularly Phase 3 completion events or study terminations — are material information that appears in trial registry updates before press releases.

Medical affairs at HS-active companies

Medical affairs teams monitor the competitive HS pipeline to anticipate new market entrants, identify key opinion leader publication activity, and prepare for upcoming conference data presentations. Daily trial registration monitoring surfaces competitive signals as they post.

Frequently asked questions